BioSpace News Archive

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019, after the closing of the U.S. financial markets.

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its second quarter ended September 30, 2019 and provided an update on recent developments.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, is supporting the efforts of Beyond Type 1, a global diabetes advocacy organization, in fielding its largest marathon team in history, made up of 30 runners with a combined 385 years of experience living with type 1 diabetes.

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced the completion of its previously announced registered direct offering to a healthcare-focused institutional investor priced at-the-market,

Atrion Corporation announced that for the third quarter ended September 30, 2019 revenues totaled $38.9 million down slightly from $39.3 million for the same period in 2018.

Flexion Therapeutics, Inc. announced equity inducement grants to four new employees consisting of an aggregate of 14,700 stock options and 2,500 restricted stock units.

Dicerna™ Pharmaceuticals, Inc., a leading developer of investigational RNA interference therapeutics, announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 209,500 shares of common stock to be distributed among 13 new employees, with a grant date of November 1, 2019

Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International Financial Reporting Standards.

Toyobo Co., Ltd. has signed a memorandum of understanding on joint pilot test with Saline Water Conversion Corporation to realize the practical application of a new brine concentration membrane technology that efficiently uses concentrated brine discharged by seawater desalination plants.

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2019 ended September 30th, 2019, after the market closes on Thursday, November 7th, 2019, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time